Chounta V, et al. Patient-reported outcomes after 152 weeks of HIV maintenance therapy with long-acting cabotegravir + rilpivirine in the phase 3b ATLAS-2M study. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

Zoom in or click an area to see more details.

×
X
⟨
⟩
×
 
This content was acquired following an unsolicited medical information enquiry by a healthcare professional.  Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license.  In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Yes

No

Connect With Our Medical Experts

Find My ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Talk to a Medical Expert

Connect now with a live ViiV Medical Expert.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1‑888‑226‑8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Our Response to COVID-19

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch